Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Ophth. Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Ophth. Other
    Study Examines Effects of Delaying Treatment for Ocular Hypertension - (DGNews)
    Researchers Discover Gene That Could Help Prevent Blindness in Familial Exudative Vitreoretinopathy - (DGNews)
    Bifocals May Slow Progression of Myopia in Children - (DGNews)
    Intravitreal Triamcinolone May Slow Progression of Diabetic Retinopathy - (DGNews)
    Eye Floaters, Flashes of Light Linked to Retinal Tear, Detachment - (DGNews)

    News archive

     Recent webcasts/CME - Ophth. Other
    • Treatment Considerations for Patients With Glaucoma: A Case-Based Approach to Individualized Therapy
    • When to Start Therapy for Glaucoma: Assessing Risk and Establishing Goals of Therapy
    • What to Start: Initiating Therapy and Monitoring Response
    • Neuro-Ophthalmic Complications of Cervical Spine Manipulation
      Treatment of Dry Eye

      Webcasts/CME archive

       Recent cases - Ophth. Other
        Ophthalmic Complications Of Endoscopic Ethmoidectomy: A Case Report
        Keratoconus Associated With Choroidal Neovascularization: A Case Report
        Unusual Orbital Lymphoma Undetectable By Magnetic Resonance Imaging: A Case Report
        Exposure To Euphorbia lathyris Latex Resulting In Alkaline Chemical Injury: A Case Report
        Wolfram Syndrome Presenting With Optic Atrophy And Diabetes Mellitus: Two Case Reports

        Cases archive
          




        my personal edition > ophth. other > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        Vegamox(TM) (Moxifloxacin Hydrochloride Ophthalmic Solution) Approved in Japan for Eye Infections

        FORT WORTH, TX -- July 27, 2006 -- Alcon, Inc. announced that the Ministry of Health, Labor and Welfare in Japan has approved its Vegamox™ (moxifloxacin hydrochloride ophthalmic solution) 0.5 % for the treatment of bacterial infections of the eye including, among others, conjunctivitis and keratitis (including corneal ulcer), as well as for surgical prophylaxis.

        Vegamox solution is a fourth-generation fluoroquinolone eye drop formulated at a 0.5% concentration, providing high drug concentration throughout relevant ocular structures. Its near-neutral pH of 6.8 provides for ocular comfort. In clinical studies, Vegamox solution has demonstrated excellent efficacy and therapeutic penetration.

        Alcon Japan President Scott Manning said the approval will present an opportunity for increased sales in Japan, the world's second largest ocular anti-infective market.

        "The approval of Vegamox solution provides Alcon Japan with an important opportunity to expand its pharmaceutical offerings in Japan to include anti-infectives and more fully serve Japanese ophthalmologists," said Manning. "Because of its clinical profile and our experience with it in the U.S., where it is the number one prescribed ocular anti-infective, as well as the strong preference for fluoroquinolones by Japanese ophthalmologists, we expect it to be a strong participant in the anti-infective market in Japan. In anticipation of the commercial launch of Vegamox(TM) solution this year, we are expanding our sales force in order to reach physicians with information about how this product may contribute to the treatment of bacterial eye diseases."

        Vegamox solution is currently approved as Vigamox™ solution in more than 40 countries around the world.


        SOURCE: Alcon, Inc.



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2010 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send